As the 64th annual meeting of the American Society of Hematology (ASH) drew to a close in New Orleans on Tuesday, more clinical updates provided a window into the development prospects for two important programs in this therapy area.
Among other presentations on offer during the day, China-based BeiGene (HKEX: 06160) provided more data from the ALPINE trial of Brukinsa (zanubrutinib), while Swiss pharma giant Novartis (NOVN: VX) briefed the congress on results from the Phase III APPLY-PNH trial of iptacopan.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze